NasdaqGS:BIOS

Stock Analysis Report

Executive Summary

BioScrip, Inc. provides infusion and home care management solutions in the United States.

Snowflake

Fundamentals

Slightly overvalued with worrying balance sheet.

Risks

  • BioScrip has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has BioScrip's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.1%

NasdaqGS:BIOS

-1.7%

US Healthcare

0.2%

US Market


1 Year Return

2.2%

NasdaqGS:BIOS

-6.1%

US Healthcare

-0.7%

US Market

BIOS outperformed the Healthcare industry which returned -3.1% over the past year.

BIOS outperformed the Market in United States of America which returned -1.2% over the past year.


Share holder returns

BIOSIndustryMarket
7 Day-2.1%-1.7%0.2%
30 Day4.9%-2.3%-2.7%
90 Day36.5%1.6%1.6%
1 Year2.2%2.2%-4.7%-6.1%1.6%-0.7%
3 Year2.2%2.2%27.0%21.8%40.0%30.9%
5 Year-64.8%-64.8%67.4%57.6%53.8%36.8%

Price Volatility Vs. Market

How volatile is BioScrip's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioScrip undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

BioScrip's share price is below the future cash flow value, and at a moderate discount (> 20%).

BioScrip's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

BioScrip is loss making, we can't compare its value to the US Healthcare industry average.

BioScrip is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for BioScrip, we can't assess if its growth is good value.


Price Based on Value of Assets

BioScrip has negative assets, we can't compare the value of its assets to the US Healthcare industry average.


Next Steps

Future Growth

How is BioScrip expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

50.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

BioScrip's revenue is expected to grow by 4.9% yearly, however this is not considered high growth (20% yearly).

BioScrip is not considered high growth as it is expected to be loss making for the next 1-3 years.

BioScrip's revenue growth is positive but not above the United States of America market average.

Unable to compare BioScrip's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare BioScrip's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if BioScrip will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has BioScrip performed over the past 5 years?

28.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

BioScrip does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare BioScrip's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare BioScrip's 1-year growth to the US Healthcare industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if BioScrip has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

BioScrip used its assets less efficiently than the US Healthcare industry average last year based on Return on Assets.


Return on Capital Employed

It is difficult to establish if BioScrip improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is BioScrip's financial position?


Financial Position Analysis

BioScrip is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

BioScrip's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

BioScrip has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if BioScrip's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

BioScrip has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

BioScrip has less than a year of cash runway based on current free cash flow.

BioScrip has less than a year of cash runway if free cash flow continues to reduce at historical rates of -33.4% each year.


Next Steps

Dividend

What is BioScrip's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate BioScrip's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate BioScrip's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as BioScrip has not reported any payouts.

Unable to verify if BioScrip's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as BioScrip has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of BioScrip's salary, the management and board of directors tenure and is there insider trading?

1.8yrs

Average management tenure


CEO

Dan Greenleaf (54yo)

2.9yrs

Tenure

US$4,111,309

Compensation

Mr. Daniel E. Greenleaf, also known as Dan, has been the Chief Executive Officer and President at BioScrip, Inc. since September 9, 2016. Mr. Greenleaf has over 21 years of relevant experience in senior le ...


CEO Compensation Analysis

Dan's remuneration is higher than average for companies of similar size in United States of America.

Dan's compensation has increased whilst company is loss making.


Management Age and Tenure

1.8yrs

Average Tenure

54yo

Average Age

The average tenure for the BioScrip management team is less than 2 years, this suggests a new team.


Board Age and Tenure

3.3yrs

Average Tenure

57yo

Average Age

The tenure for the BioScrip board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$030 May 19
Gabelli & Company Investment Advisers, Inc.
EntityCompany
Shares824,829
Max PriceUS$2.23
BuyUS$030 May 19
GAMCO Investors, Inc.
EntityCompany
Shares727,871
Max PriceUS$2.23
SellUS$204,09730 May 19
Teton Advisors, Inc
EntityCompany
Shares107,669
Max PriceUS$2.11
BuyUS$274,23030 May 19
Teton Advisors, Inc
EntityCompany
Shares150,000
Max PriceUS$1.83
SellUS$3,69130 May 19
Gabelli & Company Investment Advisers, Inc.
EntityCompany
Shares1,800
Max PriceUS$2.05
SellUS$030 May 19
GAMCO Investors, Inc.
EntityCompany
Shares382,623
Max PriceUS$2.23
SellUS$1,066,52115 Mar 19
GAMCO Investors, Inc.
EntityCompany
Shares301,732
Max PriceUS$3.88
BuyUS$1,46715 Mar 19
Gabelli & Company Investment Advisers, Inc.
EntityCompany
Shares400
Max PriceUS$3.70
BuyUS$51,54915 Mar 19
Teton Advisors, Inc
EntityCompany
Shares15,583
Max PriceUS$3.31
SellUS$156,64715 Mar 19
Teton Advisors, Inc
EntityCompany
Shares46,166
Max PriceUS$3.57
SellUS$11,02827 Nov 18
GAMCO Investors, Inc.
EntityCompany
Shares776,691
Max PriceUS$3.62
SellUS$75,56927 Nov 18
Teton Advisors, Inc
EntityCompany
Shares22,448
Max PriceUS$3.72
BuyUS$67,55127 Nov 18
GAMCO Investors, Inc.
EntityCompany
Shares63,573
Max PriceUS$2.74

Ownership Breakdown


Management Team

  • Vito Ponzio (64yo)

    Chief Administrative Officer & Senior VP

    • Tenure: 0.0yrs
    • Compensation: US$828.22k
  • Rich Denness

    Senior VP & Chief Commercial Officer

    • Tenure: 1.1yrs
  • Dan Greenleaf (54yo)

    CEO, President & Director

    • Tenure: 2.9yrs
    • Compensation: US$4.11m
  • Bob Roose (61yo)

    Chief Procurement Officer & Senior VP

    • Tenure: 0.0yrs
    • Compensation: US$552.16k
  • John McMahon (54yo)

    VP, Controller & Chief Accounting Officer

    • Tenure: 0.8yrs
  • Steve Deitsch (46yo)

    Senior VP

    • Tenure: 2.3yrs
    • Compensation: US$1.20m
  • Kathryn Stalmack

    Senior VP

    • Tenure: 4.0yrs
    • Compensation: US$999.25k
  • Leslie McIntosh

    SVP & Chief Human Resources Officer

    • Tenure: 1.1yrs
  • Harriet Booker (53yo)

    Senior VP & COO

    • Tenure: 1.8yrs
    • Compensation: US$1.07m

Board Members

  • Steve Neumann (51yo)

    Director

    • Tenure: 2.6yrs
    • Compensation: US$192.25k
  • Michael Bronfein (63yo)

    Director

    • Tenure: 3.3yrs
    • Compensation: US$206.50k
  • Michael Goldstein (77yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: US$210.50k
  • Dan Greenleaf (54yo)

    CEO, President & Director

    • Tenure: 2.9yrs
    • Compensation: US$4.11m
  • David Golding (57yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: US$202.50k
  • R. Pate (64yo)

    Non-Executive Chairman

    • Tenure: 3.2yrs
    • Compensation: US$279.00k
  • Chris Shackelton (39yo)

    Director

    • Tenure: 4.4yrs
    • Compensation: US$188.50k

Company Information

BioScrip, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioScrip, Inc.
  • Ticker: BIOS
  • Exchange: NasdaqGS
  • Founded: 1996
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$344.912m
  • Shares outstanding: 129.18m
  • Website: https://www.bioscrip.com

Number of Employees


Location

  • BioScrip, Inc.
  • 1600 Broadway
  • Suite 700
  • Denver
  • Colorado
  • 80202
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BIOSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDAug 1996
MM6DB (Deutsche Boerse AG)YesCommon StockDEEURAug 1996
MM6XTRA (XETRA Trading Platform)YesCommon StockDEEURAug 1996

Biography

BioScrip, Inc. provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/07 23:56
End of Day Share Price2019/08/07 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.